ASTH (Astrana Health) ROE %: 7.31% (As of Mar. 2026) — Near Median


ASTH Astrana Health Inc ASTH
87 GF Score
Price $43.48
GF Value $82.34
Valuation Significantly Undervalued
! 8 Warning Signs
View Full Analysis

What is Astrana Health ROE %?

Astrana Health ASTH +2.98% 87 ROE % is 7.31% as of Mar. 2026, which is 4% above its 10-year median of 7.05. GuruFocus rates ASTH with a GF Score™ of 87/100 and a GF Value™ of $82.34 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 628 Healthcare Providers & Services companies, Astrana Health ranks worse than 55.41% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Astrana Health's annualized net income for the quarter that ended in Mar. 2026 was $58 Mil. Astrana Health's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $790 Mil. Therefore, Astrana Health's annualized ROE % for the quarter that ended in Mar. 2026 was 7.31%.

The historical rank and industry rank for Astrana Health's ROE % or its related term are showing as below:

ASTH' s ROE % Range Over the Past 10 Years
Min: -625.02   Med: 7.05   Max: 17.7
Current: 3.91

During the past 13 years, Astrana Health's highest ROE % was 17.70%. The lowest was -625.02%. And the median was 7.05%.

ASTH's ROE % is ranked worse than
55.41% of 628 companies
in the Healthcare Providers & Services industry
Industry Median: 5.72 vs ASTH: 3.91

Astrana Health  (NAS:ASTH) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=57.744/789.7795
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(57.744 / 3860.4)*(3860.4 / 2288.744)*(2288.744 / 789.7795)
=Net Margin %*Asset Turnover*Equity Multiplier
=1.5 %*1.6867*2.898
=ROA %*Equity Multiplier
=2.53 %*2.898
=7.31 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=57.744/789.7795
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (57.744 / 78.836) * (78.836 / 114.112) * (114.112 / 3860.4) * (3860.4 / 2288.744) * (2288.744 / 789.7795)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7325 * 0.6909 * 2.96 % * 1.6867 * 2.898
=7.31 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Astrana Health ROE % Related Terms


Astrana Health ROE % Historical Data

* Premium members only.

The historical data trend for Astrana Health's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astrana Health ROE % Chart

Astrana Health Annual Data
Trend Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.70 9.12 10.50 6.50 3.01

Astrana Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.67 4.99 0.19 3.09 7.31

ASTH vs MD, SGRY, ADUS: ROE % Comparison

For the Medical Care Facilities subindustry, Astrana Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astrana Health ROE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Astrana Health's ROE % distribution charts can be found below:

* The bar in red indicates where Astrana Health's ROE % falls into.


ASTH
87GF Score
Astrana Health Inc ASTH
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astrana Health ROE % Calculation

Astrana Health's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=22.487/( (712.72+779.291)/ 2 )
=22.487/746.0055
=3.01 %

Astrana Health's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=57.744/( (779.291+800.268)/ 2 )
=57.744/789.7795
=7.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 7.31% mean?
Astrana Health (ASTH) has a ROE % of 7.31% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Astrana Health and its competitors. This is near median its historical median of 7.05. According to the industry distribution chart, Astrana Health ranks #348 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 55.4%.
Is Astrana Health's ROE % too high?
Astrana Health's current ROE % of 7.31% is near median its 10-year median of 7.05. The Healthcare Providers & Services industry median ROE % is 5.72. Astrana Health's value of 7.31% is 27.8% above this industry median. Based on the distribution chart, Astrana Health ranks #348 out of 628 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Astrana Health has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's ROE % compare to MD and SGRY?
According to the Healthcare Providers & Services industry distribution chart, Astrana Health ranks #348 out of 628 companies for ROE %. This places Astrana Health in the lower half of its industry. The industry median ROE % is 5.72. Astrana Health's value of 7.31% is 27.8% above this benchmark. While the company's 10-year median is 7.05 vs. the industry median of 5.72, Astrana Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astrana Health's current ROE % of 7.31% is 27.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Astrana Health and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astrana Health's current ROE % is 7.31%, which is near median its own 10-year median of 7.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $82.34, compared to a current price of $43.48 — trading 47.2% below its estimated fair value. The current ROE % is 7.31%, which is near median its 10-year median of 7.05 and 27.8% above the Healthcare Providers & Services industry median of 5.72. Astrana Health's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Astrana Health (ASTH), the current ROE % is 7.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astrana Health (ASTH) Overvalued in 2026?

Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued. The current stock price of $43.48 is trading 47.2% below its estimated GF Value™ of $82.34. GuruFocus considers Astrana Health to be Significantly Undervalued.

Key valuation signals for ASTH:

  • ROE %: 7.31% (near median its 10-year median of 7.05)
  • GF Value™: $82.34 vs. price of $43.48 (47.2% below fair value)
  • GF Score™: 87/100 with 8 warning signs
  • Industry Position: 27.8% above the Healthcare Providers & Services median (#348 of 628)

No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Astrana Health Business Description

Other Exchanges 3AM:Germany
Address 1668 South Garfield Avenue, 2nd Floor, Alhambra, CA, USA, 91801
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
87GF Score

Get the complete analysis for ASTH

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.48
Price
$82.34
GF Value